Intravitreal dexamethasone implant in patients with persistent macular edema of variable etiologies

Nir Sorkin, Anat Loewenstein, Zohar Habot-Wilner, Michaela Goldstein

Research output: Contribution to journalArticlepeer-review


Purpose: To examine the effect of an intravitreal dexamethasone drug delivery system (DEX-DDS) in the treatment of persistent cystoid macular edema (CME) of different etiologies. Methods: Thirty-seven eyes with persistent CME were treated with DEX-DDS and analyzed for changes in best-corrected visual acuity (BCVA) and optical coherence tomography. Eyes were categorized into three groups: diabetic macular edema (DME, n = 14), vein occlusion (n = 15) and uveitis (n = 7). Results: The mean follow-up was 22 ± 6.9 weeks. BCVA improved from 0.62 ± 0.38 to 0.35 ± 0.29 logMAR (p < 0.0001). Central macular thickness decreased by 184 ± 246 μm from baseline (p < 0.0001). In eyes where CME resolved and recurred, the average CME-free period was 11 weeks. The uveitis group showed faster CME resolution (2 weeks) and a longer CME-free period (20 weeks). Similar efficacy was shown for repeat DEX-DDS injections. The safety profile was good. Conclusion: DEX-DDS is beneficial in the treatment of persistent CME. In cases of uveitis, CME resolution is rapid, resulting in the longest effect duration, when compared with other CME etiologies.

Original languageEnglish
Pages (from-to)83-91
Number of pages9
Issue number2
StatePublished - 2014


  • Cystoid macular edema, persistent
  • Dexamethasone
  • Intravitreal injections
  • Ozurdex


Dive into the research topics of 'Intravitreal dexamethasone implant in patients with persistent macular edema of variable etiologies'. Together they form a unique fingerprint.

Cite this